Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics

Seres Therapeutics, Inc. (MCRB): $2.38

0.01 (-0.42%)

POWR Rating

Component Grades








Add MCRB to Watchlist
Sign Up

Industry: Biotech




#56 of 356

in industry

MCRB Price/Volume Stats

Current price $2.38 52-week high $9.49
Prev. close $2.39 52-week low $2.28
Day low $2.30 Volume 2,238,300
Day high $2.46 Avg. volume 2,228,380
50-day MA $3.59 Dividend yield N/A
200-day MA $4.93 Market Cap 305.13M

MCRB Stock Price Chart Interactive Chart >


  • Quality is the dimension where MCRB ranks best; there it ranks ahead of 82.36% of US stocks.
  • The strongest trend for MCRB is in Quality, which has been heading up over the past 177 days.
  • MCRB ranks lowest in Momentum; there it ranks in the 3rd percentile.

MCRB Stock Summary

  • SERES THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.51% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 25.18 for SERES THERAPEUTICS INC; that's greater than it is for 98.04% of US stocks.
  • With a year-over-year growth in debt of 175.78%, SERES THERAPEUTICS INC's debt growth rate surpasses 93.76% of about US stocks.
  • Stocks that are quantitatively similar to MCRB, based on their financial statements, market capitalization, and price volatility, are BPMC, SLDP, RXRX, EFTR, and SRPT.
  • Visit MCRB's SEC page to see the company's official filings. To visit the company's web site, go to

MCRB Valuation Summary

  • In comparison to the median Healthcare stock, MCRB's price/sales ratio is 36.84% higher, now standing at 2.6.
  • MCRB's EV/EBIT ratio has moved up 78.8 over the prior 100 months.

Below are key valuation metrics over time for MCRB.

Stock Date P/S P/B P/E EV/EBIT
MCRB 2023-09-22 2.6 14.8 -2.2 -2.1
MCRB 2023-09-21 2.7 15.4 -2.3 -2.2
MCRB 2023-09-20 2.6 15.1 -2.2 -2.2
MCRB 2023-09-19 2.7 15.7 -2.3 -2.3
MCRB 2023-09-18 2.7 15.6 -2.3 -2.3
MCRB 2023-09-15 2.8 16.2 -2.4 -2.4

MCRB Growth Metrics

    Its 3 year revenue growth rate is now at 345.02%.
  • Its 5 year net cashflow from operations growth rate is now at 17.76%.
  • Its 3 year net income to common stockholders growth rate is now at 9.04%.
MCRB's revenue has moved down $8,696,000 over the prior 67 months.

The table below shows MCRB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.374 -227.787 -231.362
2022-06-30 136.655 -40.463 -103.142
2022-03-31 140.702 -30.261 -86.737
2021-12-31 144.927 6.688 -65.578
2021-09-30 155.27 40.624 -33.829
2021-06-30 29.962 -112.984 -132.327

MCRB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MCRB has a Quality Grade of C, ranking ahead of 46.12% of graded US stocks.
  • MCRB's asset turnover comes in at 0.094 -- ranking 268th of 680 Pharmaceutical Products stocks.
  • ABEO, VXRT, and ARWR are the stocks whose asset turnover ratios are most correlated with MCRB.

The table below shows MCRB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 -0.662
2021-03-31 0.111 1 -0.642
2020-12-31 0.146 1 -0.751
2020-09-30 0.133 1 -1.134
2020-06-30 0.247 1 -1.379
2020-03-31 0.276 1 -1.299

MCRB Price Target

For more insight on analysts targets of MCRB, see our MCRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.57 Average Broker Recommendation 1.5 (Moderate Buy)

Seres Therapeutics, Inc. (MCRB) Company Bio

Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.

MCRB Latest News Stream

Event/Time News Detail
Loading, please wait...

MCRB Latest Social Stream

Loading social stream, please wait...

View Full MCRB Social Stream

Latest MCRB News From Around the Web

Below are the latest news stories about SERES THERAPEUTICS INC that investors may wish to consider to help them evaluate MCRB as an investment opportunity.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corp

Yahoo | September 11, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., September 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on September 6, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 91,000 shares of its common stock to two new employees, consisting of stock options to purchase an aggregate of 45,500 shares of common stock and restricted stock units ("RSUs"), cove

Yahoo | September 8, 2023

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass., September 07, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m. ET.

Yahoo | September 7, 2023

Invaio achieves first registration for citrus greening solution featuring Trecise™ technology

Invaio Sciences, a bio platform company accelerating the leap to nature-positive agriculture, today announced that its Citrus Health solution to suppress citrus greening in oranges received approval from the Florida Department of Agriculture and Community Services (FDACS) under section 24(c) of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA).

Yahoo | August 29, 2023

Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel

Seres Therapeutics, Inc.'s ( NASDAQ:MCRB ) price-to-sales (or "P/S") ratio of 4.2x might make it look like a strong buy...

Yahoo | August 9, 2023

Read More 'MCRB' Stories Here

MCRB Price Returns

1-mo -31.01%
3-mo -50.31%
6-mo -60.07%
1-year -62.93%
3-year -91.59%
5-year -67.17%
YTD -57.50%
2022 -32.77%
2021 -66.00%
2020 610.14%
2019 -23.67%
2018 -55.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!